Tirzepatide 30mg

$700.000

Tirzepatide 30 mg, high-purity lyophilized compound for scientific research. HPLC-verified batch.

Order via WhatsApp

We confirm availability, payment method and delivery time. No commitment.

SKU: PG-TIRZEPATIDE-30-MG-EN Category: Brand:

Description

Tirzepatide 30mg is a high-purity lyophilized research compound supplied for scientific research and laboratory development only. This presentation contains 30 mg per vial. Every batch is analyzed by HPLC for purity and by mass spectrometry for identity; the certificate of analysis is available on request.

Mechanism of action

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. Its affinity for the GIP receptor is comparable to native GIP, while its GLP-1 receptor affinity is about five times lower than native GLP-1, a deliberate feature of its design. A C20 fatty diacid binds albumin at roughly 99 %, giving a mean half-life of 5.4 days. The approved medicine (sold under brands such as Mounjaro and Zepbound) and this research reagent are not the same thing.

Mechanism of action, receptor by receptor

Tirzepatide was the first dual incretin agonist to reach clinical use. One design detail is often overlooked and explains much of its behavior: it does not activate both receptors with the same intensity.

GIP receptor (GIPR)

Tirzepatide’s affinity for the GIP receptor is comparable to that of native GIP. On this pathway it behaves almost like the natural hormone.

The GIP receptor is expressed in pancreatic beta cells and, notably, in adipose tissue. That second location concentrates the research interest: the GIP pathway is studied for its role in energy-substrate handling and adipocyte sensitivity, ground the GLP-1 pathway does not cover.

GLP-1 receptor (GLP-1R)

Here is the asymmetry. Tirzepatide’s affinity for the GLP-1 receptor is about five times lower than that of native GLP-1. It is not a design flaw: it is a deliberate feature of the molecule’s profile.

The GLP-1 pathway contributes satiety signaling, slower gastric emptying and glucose-dependent insulin secretion. Partial rather than maximal activation is part of what is studied when dual agonism is compared with GLP-1 agonism alone.

Pharmacokinetics

Tirzepatide carries a 20-carbon diacid fatty acid (C20) that binds plasma albumin with very high affinity: about 99 % of the compound circulates bound to that protein.

That binding determines its duration. The mean half-life is 5.4 days, with roughly 1.7-fold accumulation on repeated administration and steady state reached after four weeks of weekly dosing.

Structural modificationC20 diacid fatty acid
Albumin binding≈ 99 %
Mean half-life5.4 days
Accumulation≈ 1.7-fold with repeated doses
Steady stateAt 4 weeks
GIPR affinityComparable to native GIP
GLP-1R affinity≈ 5 times lower than native GLP-1

Elimination occurs through three documented routes: beta-oxidation of the C20 fatty acid, proteolytic cleavage of the peptide backbone and amide hydrolysis. Metabolites are excreted in urine and feces.

What the published trials show

Tirzepatide has two separate clinical-trial programs, and they should not be confused because they study different things:

  • SURPASS: type 2 diabetes. Nine trials evaluating the molecule on top of different background therapies. HbA1c reductions of up to 2.58 % were reported.
  • SURMOUNT: obesity. In SURMOUNT-1, in adults with obesity or overweight and at least one associated comorbidity, the 15 mg group showed a mean body-weight reduction of 20.9 % at 72 weeks, versus 3.1 % in the placebo group.

In SURMOUNT-5, a 72-week phase 3b trial, a greater weight reduction than with semaglutide was reported.

These results belong to the approved medicine, administered under medical supervision in selected populations with controlled dose escalation. They do not describe the laboratory material on this page.

Regulatory status

Unlike Retatrutide, tirzepatide does have regulatory approval as a medicine in several countries, marketed under brands registered by its originator laboratory.

That distinction matters and must be understood properly: the approved medicine and the research material are not the same thing. A medicine is manufactured under pharmaceutical standards, comes as a finished presentation, carries an approved label and is dispensed by prescription.

Exists as a medicineYes, approved in several countries
This productLyophilized reagent for research
INVIMA sanitary registrationThis material has none
Intended destinationLaboratory and scientific research

About brand names: tirzepatide is marketed as a medicine under brands registered by its originator laboratory, among them Mounjaro and Zepbound. This material is not Mounjaro or Zepbound, nor any other pharmaceutical presentation: it is a lyophilized reagent for laboratory research, without sanitary registration. Anyone looking for the medicine should go to a pharmacy with a prescription.

Safety and documented effects

It is the most frequently asked question about these molecules, and it deserves a precise answer rather than evasion.

Two things that are usually confused must be separated.

What the clinical literature reports

The trials of the investigational or approved drugs document a well-characterized adverse-effect profile, predominantly gastrointestinal (nausea, vomiting, diarrhea, constipation), generally dose-dependent and more frequent during initial dose escalation. That information comes from studies with thousands of participants under medical supervision and is recorded in the approved labels and the trial publications.

What applies to a laboratory reagent

This material has no established safety profile for human use, and the reason is structural, not a technicality:

  • It is not manufactured under finished-product pharmaceutical standards.
  • It carries no approved label or package insert.
  • It has not passed a regulator’s review for that purpose.
  • It has no INVIMA sanitary registration.

Attributing the medicine’s safety profile to it would be incorrect: they are different things, produced under different standards and intended for different uses. Anyone looking for the medicine should go to a pharmacy with a prescription.

Specifications

CompoundTirzepatide
Vial content30 mg
FormLyophilized powder in a sealed vial
PurityVerified by HPLC, ≥ 99 %
IdentityConfirmed by mass spectrometry
StorageUnreconstituted: controlled room temperature, away from light. Reconstituted: 2–8 °C.
DocumentationCertificate of analysis per batch, on request
Intended useScientific research and laboratory development

Quality control and certificate of analysis

Every lot is analyzed before it is offered. Two independent tests are involved, and they answer different questions:

  • HPLC (high-performance liquid chromatography) measures purity: what proportion of the sample is a single compound. The specification for this material is ≥ 99 %.
  • Mass spectrometry confirms identity: that the compound’s measured mass matches the theoretical mass of the expected sequence.

Purity and identity are not the same thing: a sample can be 99 % pure of something that is not what was ordered. That is why both are reported. The certificate of analysis (CoA) of the lot, with its lot number, chromatogram and purity figure, is sent on request through WhatsApp before or after the order. If you are comparing suppliers, our guide on how to verify a peptide supplier explains how to read a CoA and which questions to ask.

Reconstitution and handling

The material ships lyophilized, its most stable form for transport and storage. For use in a protocol it is reconstituted with bacteriostatic water, which contains benzyl alcohol as a preservative and allows several draws from the same vial.

  1. Let the vial reach room temperature before opening, to avoid condensation.
  2. Disinfect both stoppers with isopropyl alcohol.
  3. Add the water slowly down the inner wall of the vial, never directly onto the powder.
  4. Swirl gently until fully dissolved. Do not shake: agitation can denature the peptide.
  5. Label with date and concentration, and refrigerate at 2–8 °C protected from light.

Bacteriostatic water available: Bacteriostatic Water 10 ml · Bacteriostatic Water 3 ml · Bacteriostatic Water 30 ml.

Storage and stability

Lyophilized peptides are stable compounds when kept dry, cold and in the dark. In practice:

  • Unopened, lyophilized: controlled room temperature is acceptable for transport and short periods; for storage beyond a few weeks, keep refrigerated (2–8 °C) or frozen (−20 °C), always protected from light. Let the vial reach room temperature before opening so that no condensation forms on the powder.
  • Reconstituted: refrigerate at 2–8 °C, protected from light, and use within the time frame of the protocol. Do not freeze the reconstituted solution repeatedly: freeze–thaw cycles degrade peptides.
  • Multi-draw vials: when reconstituted with bacteriostatic water, the benzyl alcohol inhibits bacterial growth after the stopper is pierced, which is what allows several draws; the usual laboratory convention is to discard a multi-dose vial 28 days after the first puncture.

Research lines

  • Glucose homeostasis and incretin signaling
  • Body composition under controlled protocols
  • Dual versus single GLP-1 agonism

Other presentations of Tirzepatide

Related guides

Technical articles from our research-guides section that expand on this compound and on how to evaluate a supplier:

Frequently asked questions

Is this Mounjaro or Zepbound?

No. Those are approved pharmaceutical products dispensed by prescription. This is a lyophilized research reagent with no sanitary registration; it does not replace them.

What is its half-life?

A mean of 5.4 days, with steady state reached after about four weeks of weekly administration in clinical studies.

What is the half-life of Tirzepatide?

The mean half-life is 5.4 days, with steady state reached after four weeks of weekly administration. That duration comes from its C20 diacid fatty acid, which binds plasma albumin at approximately 99 %.

Does it activate both receptors equally?

No, and that is a deliberate design feature. Its affinity for the GIP receptor is comparable to native GIP, while its affinity for the GLP-1 receptor is about five times lower than native GLP-1. That asymmetry defines its profile.

Is this the same as Mounjaro or Zepbound?

No. The medicine is manufactured under pharmaceutical standards, comes as a finished presentation with an approved label and is dispensed by prescription. This material is a lyophilized reagent for laboratory research, without sanitary registration, and does not replace it.

Is this product safe?

It has no established safety profile for human use, and not on a technicality: it is not manufactured under finished-product pharmaceutical standards, carries no approved label or insert, has not passed regulatory review for that purpose and has no INVIMA sanitary registration. It is material intended for the laboratory.

What side effects does the literature report?

Clinical trials of the drugs in this family document a predominantly gastrointestinal profile (nausea, vomiting, diarrhea, constipation), dose-dependent and more frequent during initial escalation. That information refers to the medicine administered under medical supervision, not to this material.

What does the certificate of analysis include?

The lot number, the HPLC chromatogram with the purity figure (specification ≥ 99 %) and the mass-spectrometry identity confirmation. It is sent on request through WhatsApp, before or after the order.

How should it be stored?

Lyophilized: cold, dry and in the dark; refrigerated or frozen for long storage, with the vial brought to room temperature before opening. Reconstituted: 2–8 °C, protected from light, without repeated freezing.

How do I place an order?

Through WhatsApp, in English or Spanish. We confirm availability, shipping cost to your city or country and the payment method before closing the order. There is no online checkout and we do not store card data.

How is it shipped?

Lyophilized, in discreet packaging with a tracking number, across Colombia and to the United States and Spain. Orders are confirmed on WhatsApp in English or Spanish.

References

  • Schneck K et al. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: Pharmacometrics & Systems Pharmacology, 2024.
  • Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 2021.
  • Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
  • SURPASS (type 2 diabetes) and SURMOUNT (obesity) clinical-trial programs.

The references support the mechanism, pharmacokinetic and clinical-development data for the molecule. They do not concern this product.

Product intended exclusively for scientific research and laboratory development. Not for human or animal consumption. It is not a medicine and holds no INVIMA sanitary registration. The information on this page describes published research lines and does not constitute medical advice.

Reviews

There are no reviews yet.

Be the first to review “Tirzepatide 30mg”

Your email address will not be published. Required fields are marked *